Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

It comes in a small pen-like device that ... issues,” notes Dr Pillai. Generic versions are expected in the next couple of years, and Indian pharmaceutical companies are preparing for wider ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

Biocon, one of India’s leading drugmakers, is aiming to tap into the growing weight-loss market by seeking approvals for generic versions of Ozempic and Wegovy as their patents near expiry next ...

Over 60 novel drug candidates are in late-stage clinical trials in China, and these will potentially compete directly with US ...

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as ...

Novo has, notably, kept up with its patent fees in the US, and generic semaglutide won't hit American shelves until at least 2032 — but as Saynor alluded to, they might be able to drive up to ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.

Medicare drug plans generally cover the oral form of semaglutide for FDA-approved uses. Learn more about coverage and costs.

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.